Boehringer Ingelheim and 3T Biosciences in cancer research agreement

10 Jan 2023
www.pmlive.com
License out/inImmunotherapy
Boehringer Ingelheim and 3T Biosciences in cancer research agreement
Preview
Source: PMLiVE
Boehringer Ingelheim (Boehringer) and 3T Biosciences (3T) have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs, the companies announced.
The partnership will see Boehringer input its patient-derived T-cell receptor (TCR) data into 3T’s discovery platform, 3T TRACE, with the aim of identifying novel antigen targets for cancer immunotherapies.
The immunotherapy company’s platform is designed to improve the identification of novel shared TCR targets and screening of TCRs by combining high-diversity target libraries with active machine learning, potentially leading to tumour-specific, safer therapies that can be delivered at higher doses.
“3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond,” said 3T’s president and chief executive officer, Stefan Scherer. "By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumour indications and across patient populations.”
Under the terms of the agreement, 3T will receive an upfront payment and research and development support from Boehringer and will be eligible to receive up to $268m in discovery, preclinical, clinical, regulatory and commercial milestones, as well as royalties on future product sales. Boehringer will also be eligible to receive royalties on future product sales by 3T arising from the agreement.
Lamine Mbow, global head of cancer immunology and immune modulation at Boehringer, said: “Through our new partnership with 3T, we aim to accelerate and expand our pipeline of first-in-class T-cell based therapies for patients affected by cancer."
When 3T announced its launch in August 2022, the company said it had exclusively in-licenced a precise antibody-based peptide-HLA therapeutic discovery platform, along with development-stage MAGE-A3 TCR-T assets from Stanford University to rapidly expand its therapeutic portfolio.
"The combination of the TCR-mimetic discovery platform with the 3T-TRACE platform uniquely positions 3T to rapidly generate therapeutics targeting pHLA targets that are devoid of off-target cross-reactivity targeting,” Scherer said at the time of the announcement.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.